<DOC>
	<DOCNO>NCT00002519</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy paclitaxel combination radiation therapy chest patient previously untreated stage III non-small cell lung cancer surgically remove .</brief_summary>
	<brief_title>Paclitaxel Plus Radiation Therapy Treating Patients With Untreated Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose paclitaxel combine standard thoracic radiotherapy patient locally advance non-small cell lung cancer . II . Determine plasma level paclitaxel patient . III . Determine effect regimen tumor cell cycle distribution patient . OUTLINE : This dose-escalation study paclitaxel . Patients undergo standard thoracic radiotherapy 5 day week 7 week . Patients receive paclitaxel IV continuously begin 48 hour initiate radiotherapy continue last day radiotherapy . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-5 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 5 patient experience dose-limiting toxicity . Patients follow monthly 2 year . PROJECTED ACCRUAL : A total 3-5 patient per dose level accrue study within 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated nonsmall cell lung cancer amenable potentially curative surgery due following : Direct invasion mediastinum , heart , great vessel , trachea , esophagus , vertebral body , carina tumor ( T4 ) Cytologically positive scalene supraclavicular node Mediastinal contralateral hilar node 3 cm great CT , without pathological confirmation Pathologically positive mediastinal contralateral hilar node mediastinoscopy Chamberlain procedure ( N2 N3 ) Medically inoperable stage IIIA disease ( e.g. , resection would result insufficient pulmonary volume ) allow No distant metastases No pleural effusion ( regardless fluid cytology ) Evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Hematopoietic : WBC normal Platelet count normal Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) Transaminases great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine le 2.0 mg/dL Cardiovascular : No significant coronary artery disease No document myocardial infarction No angina , arrhythmia , congestive heart failure require medication Pulmonary : FEV1 great 1 liter pO2 great 55 mm Hg room air pCO2 less 45 mm Hg room air Other : No prior severe hypersensitivity reaction product contain Cremaphor EL No clinical evidence preexist polyneuropathy Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic irradiation Surgery : See Disease Characteristics Other : No concurrent medication know alter cardiac conduction cause bradycardia ( e.g. , digoxin , beta blocker , calcium channel blocker )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>